Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Conclusion Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Chemotherapy | Clinical Trials | CT Scan | Immunotherapy | OBGYN | PET Scan | Serous Carcinoma